Nonetheless, research on ketamine’s chemistry might help to identify mechanisms for addressing treatment-resistant depression that are based on glutamate-driven neuroplasticity. Indeed, pharmaceutical companies have already begun to investigate other NMDA-receptor antagonists, together with drugs that act on a different part of the glutamate system, as possible treatments for depression.
尽管如此，克他命化学方面的研究仍有助于认识基于谷氨酸推动的神经可塑性的顽固抑郁症治疗机制。事实上，制药公司已开始研究其他NMDA受体拮抗剂试图与作用于谷氨酸系统的不同部分的药物相结合作为可能的抑郁症疗法。这方面的研究有望最终产生一个全新的抗抑郁药物种类，拯救全世界几百万人。